Grufity logo
Grufity logo
EFTR

EFTR - eFFECTOR Therapeutics, Inc. Stock Price, Fair Value and News

00
Market Closed as of 15 Jun 2026, 04:00 pm ET

Price Targets

EFTR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EFTR Price Action

EFTR RSI Chart

EFTR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EFTR Valuation

Market Cap

0

Price/Earnings (Trailing)

0

Price/Sales (Trailing)

0

EV/EBITDA

0.2

Price/Free Cashflow

0

EFTR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

EFTR Fundamentals

EFTR Revenue

EFTR Earnings

EFTR Profitability

Free Cashflow Yield

0%

EFTR Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2022-2.5M3.6M3.9M
2021-28.5M15.0M1.4M
2020---42.0M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About eFFECTOR Therapeutics, Inc.

EFTR
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
 CEO
 WEBSITEhttps://effector.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES15

eFFECTOR Therapeutics, Inc. Frequently Asked Questions

EFTR is the stock ticker symbol of eFFECTOR Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of eFFECTOR Therapeutics, Inc. is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, EFTR's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EFTR PE ratio will change depending on the future growth rate expectations of investors.